Headlands Technologies LLC Sells 34,924 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Headlands Technologies LLC lessened its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 63.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,185 shares of the biotechnology company’s stock after selling 34,924 shares during the period. Headlands Technologies LLC’s holdings in Ironwood Pharmaceuticals were worth $89,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Pacer Advisors Inc. increased its position in shares of Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after buying an additional 450,949 shares in the last quarter. State Street Corp raised its position in shares of Ironwood Pharmaceuticals by 7.3% during the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after purchasing an additional 677,024 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock valued at $14,652,000 after purchasing an additional 13,028 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Ironwood Pharmaceuticals by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock valued at $8,786,000 after purchasing an additional 78,969 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Ironwood Pharmaceuticals by 7.2% in the 4th quarter. Bank of New York Mellon Corp now owns 978,135 shares of the biotechnology company’s stock valued at $4,333,000 after purchasing an additional 65,357 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on IRWD shares. Craig Hallum cut their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. JMP Securities reduced their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research note on Thursday, January 30th. Finally, StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 29th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.60.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. This represents a 10.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 192,381 shares of company stock worth $338,591 in the last 90 days. Corporate insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Trading Down 1.5 %

Ironwood Pharmaceuticals stock opened at $1.34 on Monday. Ironwood Pharmaceuticals, Inc. has a 1-year low of $1.25 and a 1-year high of $8.45. The company has a fifty day simple moving average of $1.81 and a 200 day simple moving average of $3.27. The company has a market cap of $214.44 million, a P/E ratio of -44.67 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. On average, equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.